Envestnet Portfolio Solutions’s Charles River Laboratories CRL Stock Holding History

Envestnet Portfolio Solutions’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,679	Closed	-$704K	–	1543
2025 Q1	$704K	Sell	4,679 -2,524	-35%	-$423K	﹤0.01%	922
2024 Q4	$1.33M	Sell	7,203 -2,074	-22%	-$400K	﹤0.01%	815
2024 Q3	$1.83M	Sell	9,277 -429	-4%	-$89.2K	0.01%	689
2024 Q2	$2.01M	Buy	9,706 +75	+0.8%	+$17K	0.01%	637
2024 Q1	$2.61M	Buy	9,631 +200	+2%	+$47.8K	0.01%	555
2023 Q4	$2.23M	Sell	9,431 -74	-0.8%	-$14.6K	0.01%	565
2023 Q3	$1.86M	Buy	+9,505	New	+$1.95M	0.01%	557

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Envestnet Portfolio Solutions's CRL Position: Q2 2025 in Review

Envestnet Portfolio Solutions sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 4,679 shares — an estimated $704K sold.

Envestnet Portfolio Solutions first reported a position in CRL in Q3 2023 and held it in 7 quarters. The position peaked at $2.61M in Q1 2024. 519 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

Envestnet Portfolio Solutions reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
Envestnet Portfolio Solutions sold 4,679 Charles River Laboratories shares in Q2 2025, an estimated $704K.
Envestnet Portfolio Solutions first reported a position in Charles River Laboratories in Q3 2023 and held it in 7 quarters.
Envestnet Portfolio Solutions's Charles River Laboratories position peaked at $2.61M in Q1 2024.
519 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on Envestnet Portfolio Solutions's 13F filing for Q2 2025, filed 25 Jul 2025.